Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 9/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | PLG | P00747 | 2/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | PLAT | P00750 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14999902 | 1.00 | LARS1 (0.52) | LARS1F2ALDH1A1PLGF10 | |
| SCHEMBL15000276 | 0.92 | LARS1 (0.53) | LARS1F2ALDH1A1PLGKDM4E | |
| SCHEMBL3085973 | 0.92 | LARS1 (0.53) | LARS1F2ALDH1A1PLGKDM4E | |
| SCHEMBL3093732 | 0.91 | LARS1 (0.44) | LARS1F2ALDH1A1PLGF10 | |
| SCHEMBL13152388 | 0.91 | LARS1 (0.50) | LARS1F2ALDH1A1 | |
| SCHEMBL18383338 | 0.91 | LARS1 (0.50) | LARS1F2ALDH1A1 | |
| SCHEMBL18387777 | 0.91 | LARS1 (0.50) | LARS1F2KMT2A | |
| SCHEMBL15000058 | 0.90 | LARS1 (0.50) | LARS1F2PLGF10PLAT | |
| SCHEMBL15000268 | 0.90 | LARS1 (0.50) | LARS1F2ALDH1A1KDM4EKMT2A | |
| SCHEMBL15000247 | 0.90 | LARS1 (0.49) | LARS1F2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | LARS1 1976/4885F2 4128/4885ALDH1A1 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.